The immune response elicited by this DC-based cancer vaccine strategy includes the direct activation of TAA-specific CD4+ and CD8+ T cells in conjunction with indirect activation of innate immune cells, namely natural killer (NK) cells, NK T cells, and macrophages [4]. Here, CD8A is linked to cancer.